Zymo Gets $6M in Q2 Recothrom Sales

other

▤ Summary

Zymo Gets $6M in Q2 Recothrom Sales Xconomy Seattle — ZymoGenetics, the Seattle-based biotech company, said today that it generated $6 million in second-quarter sales of recombinant thrombin (Recothrom).That performance is an improvement on the $4.5 million the company reported in the first quarter, and puts ZymoGenetics (NASDAQ: ZGEN) on pace to reach its 2009 sales forecast of $25 million to $35 million.The company trimmed its net loss to $27 million in the second quarter, and had $118.2 million in cash on the balance sheet at the end of June.

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies